CRISPR Therapeutics
CRSP
CRSP
411 hedge funds and large institutions have $7.23B invested in CRISPR Therapeutics in 2020 Q4 according to their latest regulatory filings, with 138 funds opening new positions, 132 increasing their positions, 88 reducing their positions, and 35 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
6% more call options, than puts
Call options by funds: $294M | Put options by funds: $278M
1.93% less ownership
Funds ownership: 68.24% → 66.31% (-1.9%)
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
Holders
411
Holding in Top 10
6
Calls
$294M
Puts
$278M
Top Buyers
| 1 | +$299M | |
| 2 | +$34.9M | |
| 3 | +$34.7M | |
| 4 |
Jane Street
New York
|
+$26.9M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$25M |
Top Sellers
| 1 | -$112M | |
| 2 | -$90.5M | |
| 3 | -$48.7M | |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$43.3M |
| 5 |
Renaissance Technologies
New York
|
-$37M |